

2nd Meeting

European Myeloma Network

EMN

Program

Virtual | March 3-6, 2021

FACULTY

Annalisa	Bernardini	<i>Turin, Italy</i>
Juan	Bladé	<i>Barcelona, Spain</i>
Mario	Boccardo	<i>Turin, Italy</i>
Niccolò	Bolli	<i>Milan, Italy</i>
Frank	Bridoux	<i>Poitiers, France</i>
Annemiek	Broijl	<i>Rotterdam, The Netherlands</i>
Michele	Cavo	<i>Bologna, Italy</i>
Gordon	Cook	<i>Leeds, United Kingdom</i>
Faith E.	Davies	<i>New York, USA</i>
Michel	Delforge	<i>Leuven, Belgium</i>
Christoph	Driessen	<i>St. Gallen, Switzerland</i>
Brian G.M.	Durie	<i>North Hollywood, USA</i>
Corien M.	Eeltink	<i>Amsterdam, The Netherlands</i>
Hermann	Einsele	<i>Würzburg, Germany</i>
Francesca	Gay	<i>Turin, Italy</i>
Hartmut	Goldschmidt	<i>Heidelberg, Germany</i>
Roman	Hajek	<i>Ostrava, Czech Republic</i>
Graham	Jackson	<i>Newcastle upon Tyne, United Kingdom</i>
Martin	Kaiser	<i>London, United Kingdom</i>
Efstathios	Kastritis	<i>Athens, Greece</i>
Marie Josee	Kersten	<i>Amsterdam, The Netherlands</i>
Lla - Lanny	Kirsch	<i>Seattle, USA</i>
Sigurdur	Kristinsson	<i>Stockholm, Sweden</i>
Alessandra	Larocca	<i>Turin, Italy</i>
Xavier	Leleu	<i>Poitiers, France</i>
Sagar	Lonial	<i>Atlanta, USA</i>
Heinz	Ludwig	<i>Wien, Austria</i>
Maria-Victoria	Mateos	<i>Salamanca, Spain</i>

Eline	Menu	<i>Brussels, Belgium</i>
Paolo	Milani	<i>Pavia, Italy</i>
Monique C.	Minnema	<i>Utrecht, The Netherlands</i>
Mohamad	Mohty	<i>Paris, France</i>
Philippe	Moreau	<i>Nantes, France</i>
David L.	Murray	<i>Rochester, USA</i>
Inger S.	Nijhof	<i>Amsterdam, The Netherlands</i>
Michael	O'Dwyer	<i>Galway, Ireland</i>
Enrique M.	Ocio	<i>Santander, Spain</i>
Bruno	Paiva	<i>Pamplona, Spain</i>
Giovanni	Palladini	<i>Pavia, Italy</i>
Charlotte	Pawlyn	<i>London, United Kingdom</i>
Torben	Plesner	<i>Veje, Denmark</i>
Marc-Steffen	Raab	<i>Heidelberg, Germany</i>
Noopur	Raje	<i>Boston, USA</i>
Leo	Rasche	<i>Würzburg, Germany</i>
Paula	Rodriguez Otero	<i>Pamplona, Spagna</i>
Fredrik Hellem	Schjesvold	<i>Oslo, Norway</i>
Hans	Schreurs	<i>Brussels, Belgium</i>
Pieter	Sonneveld	<i>Rotterdam, The Netherlands</i>
Evangelos	Terpos	<i>Athens, Greece</i>
Steven P.	Treon	<i>Boston, USA</i>
Saad	Usmani	<i>Charlotte, USA</i>
Niels	van de Donk	<i>Amsterdam, The Netherlands</i>
Katja Christina	Weisel	<i>Hamburg, Germany</i>
Elena	Zamagni	<i>Bologna, Italy</i>
Sonja	Zweegman	<i>Amsterdam, The Netherlands</i>

WEDNESDAY, MARCH 3, 2021

13.45-14.00 **OPENING CEREMONY**

14.00-14.45 **FROM MGUS TO SMM TO MM:
FROM BENCH TO BEDSIDE**

Chairpersons: S. Kristinsson, S. Lonial

The role of the immunomicroenvironment in evolving myeloma precursor states - **N. Bolli**

The biology and treatment of MGUS of clinical significance - **M.C. Minnema**

SMM: what is it and how to treat? - **S. Lonial**

15.00-16.00 **CELGENE - A BRISTOL MEYERS SQUIBB COMPANY
SPONSORED SYMPOSIUM**

Harnessing the Immune System in Multiple Myeloma

Chairperson: N. van de Donk

Introduction: the importance of the immune microenvironment in multiple myeloma - **N. van de Donk**

Broad immune stimulation in myeloma: the role of cereblon modulator - **F. Davies**

Targeted immune stimulation in myeloma: immunotherapies - **M.V. Mateos**

Targeted immune stimulation in Myeloma: cellular Therapies - **N. Raje**

Discussion

16.15-17.00 **FROM BENCH TO BEDSIDE SESSION
GENOMICS IN MM**

Chairpersons: B. Paiva, P. Sonneveld

Short introduction of an expert in the field setting the stage - **P. Sonneveld**

What is high risk disease? - **M. Kaiser**

Are we ready to make a change in the treatment of high risk disease? - **C. Pawlyn**

17.15-18.15 **AMGEN SPONSORED SYMPOSIUM
The cycle of evolution in multiple myeloma management
what's around the next corner?**

Chairperson: K. Weisel

Introduction - **K. Weisel**

Guiding the way - Is it time for biomarker - driven treatment in myeloma? - **M. Kaiser**

At the crossroads - Retreat or switch? - **K. Weisel**

On the horizon - Novel models of interaction between patient and care team - **H. Ludwig**

Discussion

18.30-19.15 **RESPONSE MONITORING IN MULTIPLE MYELOMA**

Chairpersons: H. Ludwig, B. Paiva

M-proteine detection; a matter of mass or velocity? - **D. Murray**

MRD detection - how, when and what then? - **B. Paiva**

Shedding light by PET-scans? - **E. Zamagni**

THURSDAY, MARCH 4, 2021

14.00-15.00 **ELDERLY PATIENTS WITH MYELOMA**

Chairpersons: M. Boccadoro, S. Zweegman

Short introduction by an expert in the field to set the stage - **S. Zweegman**

How to treat fit non-Tx eligible patients? - **M. Boccadoro**

How to treat unfit and frail patients - **A. Larocca**

Novel trial designs based on aging instead of age? - **G. Cook**

15.15-16.15 **YOUNG PATIENTS WITH MYELOMA**

Chairpersons: P. Moreau, P. Sonneveld

Short introduction by an expert in the field to set the stage - **M. Cavo**

First line treatment - **F. Gay**

To maintain or not and how? - **G. Jackson**

Optimal treatment sequences at relapse - **P. Moreau**

16.30-17.30 **JANSSEN SPONSORED SYMPOSIUM**

Managing patients with MM, now and in the new normal

Chairpersons: M.V. Mateos, S. Zweegman

Welcome and introduction - **S. Zweegman**

Advances in frontline management - **S. Zweegman**

Panel discussion: **F. Gay, P. Rodríguez Otero**

Novel agents in R/R MM management - **M.V. Mateos**

Panel discussion: **F. Gay, P. Rodríguez Otero**

17.45-18.30 **SPECIAL CONDITIONS - WALDENSTRÖM MACROGLOBULINEMIA**

Chairpersons: E. Kastiris, S.P. Treon

Biology of the disease - from genotype to phenotype? - **S.P. Treon**

Treatment in front line - **E. Kastiris**

Treatment at relapse - **M.J. Kersten**

18.45-19.15 **PATIENT PERSPECTIVE: PATIENT ASSOCIATION TALK**

Chairperson: **B. Durie**

IMF - USA - **B. Durie**

MPE - Myeloma patient groups across Europe - **H. Schreurs**

FRIDAY, MARCH 5, 2021

12.45-13.45 **MEET THE EXPERT**

Simultaneous sessions in 3 virtual rooms

- Management of MM patients from a nurse's perspective **VIRTUAL ROOM 1**
A. Bernardini, C. Eeltink
- Aggressive disease in daily practice **VIRTUAL ROOM 2**
A. Broijl, K. Weisel
- RRMM in daily practice **VIRTUAL ROOM 3**
C. Driessen, H. Goldschmidt

14.00-14.30 **FROM BENCH TO BEDSIDE SESSION - MOVING OUT OF THE MARROW**

Chairpersons: F. Gay, M. Kaiser

Plasma cell leukemia - different biology, different treatment? - **S. Usmani**
Does extramedullary means extra treatment? - **X. Leleu**

14.45-15.30 **SPECIAL CONDITIONS**

AL AMYLOIDOSIS & LIGHT CHAIN DEPOSITION DISEASE

Chairpersons: E. Kastiris, G. Palladini

AL Amyloidosis: mechanisms of disease and biomarkers - **G. Palladini**
Early diagnosis and optimal treatment - **P. Milani**
Diagnosis and management of light chain deposition disease - **F. Bridoux**

15.45-16.45 **SANOFI SPONSORED SYMPOSIUM**

Management of relapsed and refractory multiple myeloma with novel monoclonal antibody-based regimens: from evidence based considerations to clinical practice

Chairpersons: P. Moreau, P. Sonneveld

Welcome and introduction - **P. Moreau**

Mechanisms of actions of CD38 monoclonal antibodies - **N. Van de Donk**

Optimization of the treatment sequence with available treatments

in lenalidomide refractory multiple myeloma patients - Level of evidence - **E. Ocio**

AntiCD38 monoclonal antibody therapy in combinations with

pomalidomide and dexamethasone - Level of evidence - **X. Leleu**

Discussion and closing remarks

17.00-18.00 **DEBATE SESSION**

Chairpersons: F. Davies, M. Mohty

- Should all elderly receive daratumumab in first line? - YES - **M.V. Mateos** vs NO - **S. Zweegman**
- Switch induction or go directly to transplant in case of suboptimal response?
F. Schjesvold (directly to transplantation) vs **R. Hajek** (switch induction)
- Do all MGUS patients need follow-up? - YES - **S. Kristinsson** vs NO - **J. Bladé**

18.15-19.00 **SPECIAL ATTENTION TO**

Chairpersons: H. Ludwig, I. Nijhof

Bone disease - **E. Terpos**

Cytokine release syndrome and neurologic symptoms with novel immune therapy - **N. Raje**

From bacteria to viruses - **M. Delforge**

SATURDAY, MARCH 6, 2021

12.45-13.45 MEET THE EXPERT

Simultaneous sessions in 2 virtual rooms

- SMM to treat or not
A. Broijl, S. Lonial
- Frail patients in daily practice
A. Larocca, I. Nijhof

VIRTUAL ROOM 4

VIRTUAL ROOM 5

14.00-14.40 SPONSORED LECTURES

Chairmen: M. Boccadoro, G. Cook

- LECTURE SPONSORED BY ADAPTIVE:
Application of Immunosequencing for MRD Determination - **L. Kirsch**
- LECTURE SPONSORED BY GSK:
Recent advances in approved and investigational agents targeting B-cell maturation antigen (BCMA) for relapsed/refractory multiple myeloma (RRMM)
R. Popat

15.00-15.45 JOINT EMN-EHA SYMPOSIUM

Chairpersons: M.V. Mateos, N. van de Donk

Immune therapy from rationale to treatment - **P. Sonneveld**
Current evidence for bispecifics in MM treatment - **H. Einsele**
Current evidence for CARt cells in MM treatment - **P. Rodriguez-Otero**

16.00-17.00 BEST ABSTRACTS - ORAL PRESENTATIONS

Chairpersons: C. Driessen, M. Raab, F. Schjesvold, K. Weisel

B01

INTEGRATED SYSTEMS-LEVEL ANALYSIS OF PROTEOTOXIC STRESS RECOVERY REVEALS DRUGGABLE METABOLIC VULNERABILITIES OF PROTEASOME INHIBITOR-RESISTANT MYELOMA CELLS
Saavedra-Garcia P., Roman-Trufero M., Al-Sadah H., Lopez-Jimenez E., Christoforou M., Penfold L., Parzych K., Caputo V., Blighe K., Kaiser M.F., Piazza P., Capece D., Xiong X., Miao Y., Encheva V., Thiel D., Liu Z., Snijders A.P., Franzoso G., Chaidos A., Karadimitris A., Keun H.C., Oyarzun D., Barahona M., Auner H.W. (London, Sutton, Edinburgh)

B02

RUXOLITINIB COMBINED WITH THE MCL-1 INHIBITOR S63845 IS HIGHLY EFFICIENT IN TREATING MYELOMA IN THE INA-6 XENOGRAFT MODEL
Gramatzki M., Otte A.K., Brdon J.W., Günther A., Peipp M., Burger R. (Kiel)

B03

HIGH LEVELS OF CIRCULATING PLASMA CELLS (CPC) ARE AN INDEPENDENT HIGH-RISK FEATURE BUT ARE MODULATED BY MINIMAL RESIDUAL DISEASE (MRD) NEGATIVITY IN NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) PATIENTS TREATED WITH NOVEL AGENTS
Bertamini L., Grasso M., D'Agostino M., Pascarella A., Tosi P., Monaco F., Pisani F., Bertazzoni P., Gilestro M., Capra A., Galieni P., Annibaldi O., Pavone V., Molica S., Ronconi S., Tacchetti P., Musto P., Gay F., Boccadoro M., Oliva S. (Torino, Cuneo, Venezia Mestre, Rimini, Alessandria, Roma, Milano, Ascoli Piceno, Tricase, Catanzaro, Meldola, Bologna, Bari)

B04

UNRAVELLING DRUG RESISTANCE AND SENSITIZATION TO PROTEASOME INHIBITORS USING GENOME-WIDE CRISPR-CAS9 KNOCKOUT SCREENING

Vlayen S., Kint N., De Keersmaecker K., Daelemans D., Delforge M. (*Leuven*)

B05

DARATUMUMAB PLUS LENALIDOMIDE AND DEXAMETHASONE (D-Rd) VERSUS LENALIDOMIDE AND DEXAMETHASONE (Rd) IN TRANSPLANT-INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): FRAILITY SUBGROUP ANALYSIS OF MAIA

Zweegman S., Usmani S., Hulin C., Kumar S., Plesner T., Touzeau C., Bahlis N., Basu S., Nahi H., Goldschmidt H., Quach H., Cook G., Mohty M., Venner C., Weisel K., Raje N., Hebraud B., Belhadj-Merzoug K., Benboubker L., Decaux O., Manier S., Caillot D., Pei H., Van Rampelbergh R., Uhlar C., Kobos R., Facon T. (*Amsterdam, Charlotte, Pessac, Rochester, Vejle, Nantes, Calgary, Wolverhampton, Stockholm, Heidelberg, Melbourne, Leeds, Paris, Edmonton, Hamburg, Boston, Toulouse, Creteil, Tours, Rennes, Boston, Dijon, Titusville, Beerse, Spring House, Raritan, Lille*)

B06

PREDICTORS OF EARLY RELAPSE IN TRANSPLANT-ELIGIBLE MULTIPLE MYELOMA PATIENTS TREATED WITH NOVEL AGENTS: INTEGRATED ANALYSIS OF BASELINE FEATURES AND ACHIEVEMENT OF MINIMAL RESIDUAL DISEASE NEGATIVITY

Bertamini L., Zaccaria G.M., Offidani M., Vozella F., Becco P., Belotti A., Capra A., Galli M., Morabito F., Pisani F., Galièni P., Rizzi R., Gozzetti A., Pescosta N., De Rosa L., Narni F., Gilestro M., Palmieri S., Cea M., Tosi P., Giuliani N., Musto P., Cavo M., Boccadoro M., Gay F. (*Torino, Ancona, Roma, Candiolo, Brescia, Bergamo, Cosenza, Ascoli Piceno, Bari, Siena, Bolzano, Modena, Napoli, Genova, Rimini, Parma, Rionero in Vulture, Bologna*)

B07

TREATMENT EMERGENT PERIPHERAL NEUROPATHY IN THE CASSIOPEIA TRIAL

Fokkema C., Van Der Holt B., van Duin M., Wester R., Cupedo T., Moreau P., Vermeulen J., Broyl A., Sonneveld P. (*Rotterdam, Nantes, Leiden*)

B08

REVEALING TRANSCRIPTOME DEREGULATION UPON GENOMIC COMPLEXITY IN MULTIPLE MYELOMA

Da Vià M.C., Ziccheddu B., Maeda A., Morlupi S., Dugo M., Todoerti K., Oliva S., D'Agostino M., Landgren O., Iorio F., Pettine L., Pompa A., Manzoni M., Lionetti M., Corradini P., Baldini L., Neri A., Maura F., Bolli N. (*Milan, Turin, New York, Cambridge*)

B09

TREATMENT INDUCED CYTOTOXIC T-CELL MODULATION IN MULTIPLE MYELOMA PATIENTS

Barilà G., Pavan L., Vedovato S., Berno T., Arangio Febbo M., Lo Schirico M., Teramo A., Calabretto G., Vicenzetto C., Gasparini V.R., Fregnani A., Manni S., Trimarco V., Carraro S., Facco M., Piazza F., Semenzato G., Zambello R. (*Padova*)

B10

CARTITUDE-1: PHASE 1B/2 STUDY OF CILTACABTAGENE AUTOLEUCEL IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)

Madduri D., Berdeja J., Usmani S., Jakubowiak A., Agha M., Cohen A., Stewart A., Hari P., Htut M., O'Donnell E., Munshi N., Avigan D., Deol A., Lesokhin A., Singh I., Zudaire E., Yeh T.M., Allred A., Olyslager Y., Banerjee A., Goldberg J., Schecter J., Jackson C., Deraedt W., Zhuang S., Infante J., Geng D., Wu X., Carrasco-Alfonso M., Akram M., Hossain F., Rizvi S., Fan F., Jagannath S., Lin Y., Martin T. (*New York, Nashville, Charlotte, Chicago, Pittsburgh, Philadelphia, Toronto, Milwaukee, Duarte, Boston, Detroit, Spring House, Raritan, Beerse, Piscataway, Nanjing, Rochester, San Francisco*)

B11

TECLISTAMAB, A B-CELL MATURATION ANTIGEN (BCMA) X CD3 BISPECIFIC ANTIBODY, IN RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED PHASE 1 RESULTS
Garfall A., Usmani S., Mateos M.V., Nahi H., van de Donk N., San-Miguel J., Oriol A., Rosinol L., Chari A., Bhutani M., Pei L., Verona R., Girgis S., Stephenson T., Goldberg J., Banerjee A., Krishnan A. (*Philadelphia, Charlotte, Salamanca, Stockholm, Amsterdam, Navarra, Barcelona, New York, Spring House, Duarte*)

B12

TALQUETAMAB, A G PROTEIN-COUPLED RECEPTOR FAMILY C GROUP 5 MEMBER D (GPC5D) X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (RRMM): RESULTS FROM AN ONGOING PHASE 1 STUDY
Oriol A., Berdeja J., Chari A., van de Donk N., Rodriguez-Otero P., Askari E., Mateos M.V., Minnema M., Verona R., Girgis S., Prior T., Hilder B., Russell J., Goldberg J., Krishnan A. (*Barcelona, Nashville, New York, Amsterdam, Navarra, Madrid, Salamanca, Utrecht, Spring House, Duarte*)

B13

ELOTUZUMAB ELIMINATES IMMUNOSUPPRESSIVE CD8+ CD28- T CELLS IN PATIENTS WITH MULTIPLE MYELOMA (GMMG HD6 CLINICAL TRIAL)
Awwad M.H.S., Mahmoud A., Bruns H., Echchannaoui H., Kriegsmann K., Raab M.S., Bertsch U., Munder M., Jauch A., Weisel K., Maier B., Salwender H.J., Eckstein V., Hänel M., Fenk R., Dürig J., Brors B., Benner A., Müller-Tidow C., Goldschmidt H., Hundemer M. (*Heidelberg, Erlangen, Mainz, Tübingen, Hamburg, Chemnitz, Düsseldorf, Essen*)

B14

TANDEM AUTOLOGOUS STEM CELL TRANSPLANTATION IN HIGH-RISK PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: FEASIBILITY AND PRELIMINARY RESULTS FROM THE VALENCIAN GREMI STUDY GROUP
Jiménez Castillo M., Rubio Lopes-García L., Pérez Rodríguez P.L., Legarda Campo M., Ríos Rodríguez S.J., Francés Aracil E., Blanes Company M., Cejalvo Andújar M.J., Pedreño Miñana M.J., García Fera A., García Romero Domínguez S., Ribas García P., Donato Martín E., Fernández Llavador M.J., Fernández Zarzoso M., Gómez Beltrán E., Juan Marco M.L., Marco Buades J.E., Panero Ruiz M., Sayas Lloris M.J., De la Rubia Comos J. (*Valencia, Elche, Elda, Requena, Valencia*)

B15

AUTOLOGOUS STEM CELL TRANSPLANT IN PATIENTS WITH MULTIPLE MYELOMA AND IMPAIRED RENAL FUNCTION
Cooper A., Khaliq N., Kelly G., Bulger P., Rocci A. (*Manchester*)

B16

APPLICATION OF RISK MODELS FOR SMOULDERING MYELOMA TO A REAL WORLD, SINGLE CENTRE, COHORT
Ainley L., Camilleri M., Chavda S., Mcmillan A., Lee L., Popat R., Sillito F., Yong K. (*London*)

17.15-18.00 **FROM BENCH TO BEDSIDE SESSION - IMMUNESYSTEM IN MM**

Chairpersons: M. O'Dwyer, T. Plesner

Short introduction of an expert in the field setting the stage - T. Plesner

The biology of immune resistance in MM - L. Rasche

How to overcome immune resistance in MM - N. van de Donk

18.15-19.00 **FROM BENCH TO BEDSIDE SESSION
FROM THE MICROENVIRONMENT TO OVERCOMING DRUG RESISTANCE**

Chairpersons: E. Menu, E. Ocio

Short introduction of an expert in the field setting the stage - E. Menu

The myeloma microenvironment in drug resistance - E. Menu

How to overcome microenvironment induced drug resistance and novel agents in heavily pre-treated patients - E. Ocio

19.00-19.15 **CONCLUSION & FINAL GREETINGS**

POSTER

1. BIOLOGY AND PRECLINICAL

P01
TARGETING MONOCARBOXYLATE TRANSPORTER 4 REDUCES MYELOMA CELL VIABILITY IN VITRO
Van Droogenbroeck L., Oudaert I., Maes A., Satilmis H., Vlummens P., Vandewalle N., Fendt S., Maes K., De Bruyne E., Vanderkerken K., De Veirman K., Menu E. (*Brussels, Gent, Leuven*)

P02
THE CROSS-REGULATION BETWEEN TLR4 AND HO-1/CO SIGNALING PATHWAYS WORKS AS STRESS-RESPONSIVE MECHANISM TO INCREASE UPR RESPONSE AND PROTECT MITOCHONDRIA PROMOTING BORTEZOMIB RESISTANCE
Tibullo D., Scandura G., Giallongo C., Barbato A., La Spina E., Cambria D., Dulcamare I., Romano A., Parrinello N.L., Palumbo G.A., Li Volti G., Di Raimondo F. (*Catania*)

P03
IDENTIFICATION OF NOVEL CRUCIAL REGULATORS OF IMMUNOGLOBULIN PRODUCTION IN MULTIPLE MYELOMA
Vdovin A., Jelinek T., Sahinbegovic H., Durech M., Sevcikova T., Hrdinka M., Hajek R., Simicek M. (*Ostrava*)

P04
INHIBITION OF TLR4 SIGNALING OVERCOMES BORTEZOMIB RESISTANCE IN MYELOMA PLASMA CELLS AFFECTING MITOCHONDRIAL FITNESS
Giallongo C., Tibullo D., Puglisi F., Barbato A., Romano A., Cambria D., La Spina E., Parrinello N., Conticello C., Amorini A., Li Volti G., Lazzarino G., Palumbo G.A., Di Raimondo F. (*Catania*)

P05
METABOLIC ADAPTATION OF MYELOMA CELLS TO TRYPTOPHAN DEPRIVATION
Romano A., Parrinello N.L., Scandura G., Puglisi F., Giallongo C., Barbato A., La Spina E., Tibullo D., Orfanelli U., Cenci S., Di Raimondo F. (*Catania, Milano*)

P06
A CANCER-RELATED MicroRNA SIGNATURE PREDICTS OSTEOLYTIC DISEASE AND EXHIBITS PROGNOSTIC POTENTIAL IN MULTIPLE MYELOMA
Papanota A.M., Karousi P., Kontos C.K., Liacos C., Artemaki P.I., Patseas D., Papadimitriou M., Eleutherakis-Papaiakevou E., Avgeris M., Kanellias N., Bagratuni T., Roussou M., Dialoupi I., Kastritis E., Gavriatopoulou M., Scorilas A., Dimopoulos M.A., Terpos E. (*Athens*)

P07
IMMUNOSUPPRESSIVE BONE MARROW MICROENVIRONMENT INDUCED BY MULTIPLE MYELOMA-DERIVED EXTRACELLULAR VESICLES
Lopes R., Caetano J., Barahona F., Ferreira B., Pestana C., Carneiro E., João C. (*Lisbon*)

P08
EXOME AND TRANSCRIPTIONAL PROFILING OF ABERRANT PLASMA CELLS IN LIGHT-CHAIN AMYLOIDOSIS AND MULTIPLE MYELOMA
Sevcikova T., Chyra Z., Vojta P., Puterova J., Brozova L., Zatopkova M., Grosicki S., Pour L., Stork M., Harvanova L., Mistrík M., Mikala G., Robak P., Czyz A., Debski J., Usnarska-Zubkiewicz L., Jurczynszyn A., Morgan G., Kryukov F., Budinska E., Simicek M., Jelinek T., Hrdinka M., Hajek R. (*Ostrava, Boston, Olomouc, Brno, Katowice, Bratislava, Budapest, Lodz, Wroclaw, Cracow, New York*)

P09

tRNA-DERIVED RNA FRAGMENTS IN PLASMA CELLS: PROMISING MOLECULAR BIOMARKERS OF PROGNOSIS IN MULTIPLE MYELOMA

Karousi P., Papanota A.M., Kontos C.K., Liacos C., Artemaki P.I., Patseas D., Liosi A.A., Mavrianou-Koutsoukou N., Kalioraki M.A., Fotiou D., Ntanasis-Stathopoulos I., Migkou M., Malandrakis P., Gavriatopoulou M., Kastritis E., Scorilas A., Dimopoulos M.A., Terpos E. *(Athens)*

P10

THE IMPACT OF BETA-BLOCKERS ON MULTIPLE MYELOMA CELL SURVIVAL

Satilmis H., Verheye E., Oudaert I., Vandewalle N., Fan R., De Bruyne E., Maes A., Menu E., Vanderkerken K., De Veirman K. *(Brussels)*

P11

TARGETING LACTATE PATHWAY IN TUMOR MICROENVIRONMENT (TME) MAY BE A POTENTIAL STRATEGY FOR ANTI-CANCER THERAPY IN MULTIPLE MYELOMA

Barbato A., Giallongo C., Tibullo D., Romano A., Di Raimondo F. *(Catania)*

P12

BEHAVIOUR OF CIRCULATING ENDOTHELIAL CELLS (CECs) DURING AUTOLOGOUS STEM CELLS TRANSPLANTATION (AuSCT) IN PATIENTS WITH MULTIPLE MYELOMA

Annibaldi O., Gregorj C., Tomarchio V., Di Cerbo M., Antonelli L., Armiento D., Scardocci A., Tafuri M., Circhetta E., Sarlo C., Vincenzi B., Tirindelli M.C., Avvisati G. *(Roma)*

P13

LIGHT CHAIN MULTIPLE MYELOMA FOLLOW UP: SERUM IMMUNOFIXATION VS SERUM FREE LIGHT CHAIN

Pires A., Duarte D., Chacim S., Azevedo C., Barreto J., Godinho I., Sousa E., Palmeira C., Tavares M., Pereira D., Moreira C., Espírito-Santo A., Moreira I., Domingues N., Oliveira I., Martins A., Viterbo L., Mariz J., Martins G. *(Porto)*

2. NEWLY DIAGNOSED MULTIPLE MYELOMA

P14

HIGH-RISK MULTIPLE MYELOMA PATIENTS ARE MISSED WITHOUT GENE EXPRESSION PROFILING
Van Vliet M., Chen Y., Van Beers E.H., Kuiper R., Valent E., Spaan M., Terragna C., Zamagni E., Cavo M., Oliva S., Larocca A., Haferlach T., Chng W., Waage A., Zweegman S., Sonneveld P. *(Rotterdam, Bologna, Turin, Munich, Singapore, Trondheim, Amsterdam)*

P15

IMPACT OF GAIN AND AMPLIFICATION OF 1Q IN NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) PATIENTS RECEIVING CARFILZOMIB-BASED TREATMENT IN THE FORTE TRIAL

D'Agostino M., Ruggeri M., Aquino S., Giuliani N., Arigoni M., Gentile M., Olivero M., Vincelli I.D., Capra A., Mussatto C., Ledda A., Tacchetti P., Musolino C., Cellini C., Patriarca C., Ballanti S., Calogero R., Musto P., Boccadoro M., Gay F. *(Torino, Genova, Parma, Cosenza, Reggio Calabria, Cagliari, Bologna, Messina, Ravenna, Udine, Perugia, Bari)*

P16

MINIMAL RESIDUAL DISEASE (MRD) BY MULTIPARAMETER FLOW CYTOMETRY (MFC) AND NEXT-GENERATION SEQUENCING (NGS) IN NEWLY DIAGNOSED TRANSPLANT-ELIGIBLE MULTIPLE MYELOMA (NDMM): RESULTS FROM THE FORTE TRIAL

Oliva S., Genuardi E., Petrucci M.T., D'agostino M., Auclair D., Spadano A., Jacob A.P., Cea M., De Rosa L., Gozzetti A., Ruggeri M., Capra A., Gilestro M., Pescosta N., Palmas A.D., Siniscalchi A., Kirsch I.R., Corradini P., Musto P., Boccadoro M., Zamagni E., Gay F. *(Torino, Roma, Norwalk, Pescara, Seattle, Genova, Siena, Bolzano, Nuoro, Milano, Bari, Bologna)*

P17

SINGLE VS DOUBLE TRANSPLANTATION OUTCOMES IN NEWLY DIAGNOSED MULTIPLE MYELOMA: A REAL LIFE ANALYSIS

Morè S., Corvatta L., Maracci L., Mancini G., Scortechini I., Olivieri A., Offidani M. *(Ancona)*

P18

PROGNOSTIC VALUE OF THE MINIMAL RESIDUAL DISEASE (MRD) MONITORING BY NOVEL NEXT-GENERATION FLOW (NGF) AND HEAVY + LIGHT CHAIN (HLC) IMMUNOASSAYS IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM). RESULTS FROM THE VALENCIAN GRUPO DE ESTUDIOS DE MIELOMA (GREMI), SPAIN

Remigia M.J., Sempere A., Solano C., Teruel A.I., Quiñones C., Arnao M., Marco M.J., Romero S., Amat P., Ruiz M.A., Avaria A., Ribas P., Cordon L., Andreu R., Cejalvo M.J., Blanes M., Tarin F., Pérez P.I., Carbonell-Asins J.A., De la Rubia J. (*Valencia, Gandia, Elda, Alicante*)

P19

COST EFFECTIVENESS OF NOVEL AGENTS IN THE TREATMENT OF MULTIPLE MYELOMA: A SYSTEMATIC REVIEW

McCulloch S., Perry S. (*Calgary, Vancouver*)

P20

PROGNOSTIC IMPACT OF RAPID REDUCTION OF INVOLVED LIGHT CHAIN DURING FIRST LINE THERAPY WITH BENDAMUSTINE, PREDNISONE AND BORTEZOMIB (BPV) IN MYELOMA PATIENTS

Holzhey T., Pönisch W., Wang S., Holzvogt M., Holzvogt B., Andrea M., Platzbecker U., Scholz M. (*Leipzig*)

P21

R2-ISS, A NEW RISK STRATIFICATION MODEL IN NEWLY DIAGNOSED MULTIPLE MYELOMA BY THE EUROPEAN MYELOMA NETWORK WITHIN HARMONY BIG DATA PLATFORM PROJECT

D'Agostino M., Lahuerta J.J., Wester R., Waage A., Bertsch U., Zamagni E., Mateos M.V., Larocca A., Dall'Olio D., van de Donk N.W.C.J., Cairns D., Rocchi S., Salwender H., Bladé J., van der Holt B., Castellani G., Ciccone G., Capra A., Dürig J., Bringhen S., Zweegman S., Cavo M., Goldschmidt H., Cook G., Hernandez Rivas J.M., San-Miguel J., Boccadoro M., Sonneveld P. (*Italy, Spain, the Netherlands, Norway, Germany, United Kingdom*)

P22

ON-DEMAND PLERIXAFOR FOR HEMATOPOIETIC STEM-CELL MOBILIZATION IN MULTIPLE MYELOMA: A PRELIMINARY ANALYSIS OF THE OBSERVATIONAL STUDY MOZOBL06877

Mina R., Bonello F., Milone G., Fazio F., Nozzoli C., Bongarzone V., Capra A., Marchesi F., Cetani G., Malfitano A., Rota-Scalabrini D., Ballanti S., Lemoli R.M., Tosi P., Derudas D., de Fabritiis P., Offidani M., Musto P., Corradini P., Cavo M., Boccadoro M., Larocca A. (*Torino, Catania, Roma, Firenze, Candiolo, Perugia, Genova, Rimini, Cagliari, Ancona, Bari, Milano, Bologna*)

P23

PREDICTIVE GENE EXPRESSION-BASED BIOMARKERS FOR THE TREATMENT OF MULTIPLE MYELOMA PATIENTS

Valent E., Chen Y.T., van Duin M., Troia R., Pautasso C., Kuiper R., van Beers E., van Vliet M., Haferlach T., Chng W., Zweegman S., Oliva S., Larocca A., Sonneveld P. (*Rotterdam, Turin, Munich, Singapore, Amsterdam*)

P24

PROGNOSTIC SIGNIFICANCE OF DOUBLE AND TRIPLE HIT MULTIPLE MYELOMA: ULTRA HIGH-RISK ENTITIES?

Sretenovic A., Mitrovic M., Jovanovic J., Bukumiric Z., Djordjevic V., Dencic Fekete M., Jelicic J., Perunovic Jovanovic M., Terzic T., Bila J. (*Belgrade*)

P25

TOLERABILITY OF HIGH DOSE CHEMOTHERAPY AND AUTOLOGOUS STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA PATIENTS OVER 70 YEARS: "GIMEMA WORKING GROUP LAZIO" EXPERIENCE

Rago A., Annibaldi O., Tomarchio V., Fiorini A., Fazio F., Coppetelli U., De Rosa L., Papa E., Bianchi M.P., Antolino G., Caravita di Toritto T. (*Roma*)

P26

LEN/DEX COMBINATION AS FIRST-LINE THERAPY OF FRAIL MULTIPLE MYELOMA PATIENTS: A REAL LIFE STUDY

Leotta V., Bellofiore C., Markovic U., Romano A., Di Giorgio M.A., Bulla A., Moschetti G., Scirè P., Curtopelle A., Elia F., Del Fabro V., Di Raimondo F., Conticello C. (Catania, Viagrande)

P27

EFFICACY OF MAINTENANCE AND CONTINUOUS THERAPY IN PATIENTS WITH MULTIPLE MYELOMA: INDEPENDENT NETWORK META-ANALYSIS

Luchinin A., Semochkin S. (Kirov, Moscow)

P28

IXAZOMIB-BASED INDUCTION FOLLOWED BY SINGLE-AGENT IXAZOMIB MAINTENANCE IN TRANSPLANT INELIGIBLE, NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS:

UPDATED RESULTS OF THE EMN10-UNITO TRIAL

Mina R., Larocca A., Corradini P., Cascavilla N., Liberati A.M., Pescosta N., Petrucci M.T., Ciccone G., Capra A., Patriarca F., Rota-Scalabrini D., Innao V., Bernardini A., Cea M., Zambello R., Monaco F., Belotti A., Cellini C., Galli M., Grasso M., Aquino S., Margiotta Casaluci G., De Sabbata G., Ballanti S., Offidani M., Mancuso K., Boccadoro M., Bringhen S. (Torino, Milano, San Giovanni Rotondo, Terni, Bolzano, Roma, Udine, Candiolo, Messina, Genova, Padova, Alessandria, Brescia, Ravenna, Bergamo, Cuneo, Novara, Trieste, Perugia, Ancona, Bologna)

P29

DARATUMUMAB TO ERADICATE MRD IN >VGPR MM PATIENTS AFTER FIRST LINE THERAPY: INTERIM ANALYSIS OF THE DART4MM MULTICENTER ITALIAN STUDY

Gozzetti A., Raspadori D., Bacchiari F., Pacelli P., Ciofni S., Caffarelli C., Antonioli E., Buda G., Sammartano V., Lombardo A., Galieni P., Occhini U., Liberati A.M., Staderini M., Sicuranza A., Tocci D., Crupi R., Bosi A., Petrini M., Bocchia M. (Siena, Firenze, Pisa, Terni, Ascoli Piceno, Arezzo)

P30

PHENOTYPIC AND PROGNOSTIC EVALUATION OF CIRCULATING PLASMA CELLS IN NEWLY DIAGNOSED MULTIPLE MYELOMA DETECTED WITH NEXT GENERATION FLOW CYTOMETRY

Terpos E., Kostopoulos I.V., Papanota A.M., Papadimitriou K., Malandrakis P., Rousakis P., Ntanasis-Stathopoulos I., Fotiou D., Metousis A., Kanellias N., Migkou M., Eleutherakis-Papaiakevou E., Gavriatopoulou M., Kastritis E., Tsitsilonis O.E., Dimopoulos M.A. (Athens, London)

P31

TAILORING THERAPY FOR NEWLY DIAGNOSED HIGH-RISK MYELOMA PATIENTS – FIRST RESULTS OF THE RISK-ADAPTED UMKRA OPTIMUM (MUK9) TRIAL

Jenner M., Hall A., Sherborne A., Walker K., Sharp K., Bowles K., Garg M., Lokare A., Ellis S., Jackson G., Flanagan L., Drayson M., deTute R., Owen R., Pratt G., Cook G., Brown S., Kaiser M. (Southampton, Norwich, Leicester, Birmingham, Newcastle, Birmingham, Leeds, London)

3. RELAPSED/REFRACTORY MULTIPLE MYELOMA

P32

DEPTH OF RESPONSE AND RESPONSE KINETICS OF ISATUXIMAB PLUS CARFILZOMIB AND DEXAMETHASONE IN RELAPSED MULTIPLE MYELOMA: IKEMA INTERIM ANALYSIS

Martin T., Mikhael J., Hajek R., Kim K., Suzuki K., Hulin C., Garg M., Quach H., Sia H., George A., Konstantinova T., Risse M.L., Asset G., Macé S., van de Velde H., Moreau P. (San Francisco, Phoenix, Ostrava, Seoul, Tokyo, Bordeaux, Leicester, Melbourne, Victoria, Tweed Heads, Wellington, Ekaterinburg, Vitry-Sur-Seine, Chilly-Mazarin, Cambridge, Nantes)

P33

EFFECTS OF CARFILZOMIB ON BONE METABOLISM OF PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA – THE CARMMA STUDY

Terpos E., Ntanasis-Stathopoulos I., Katodritou E., Kyrtsonis M.C., Anagnostopoulos A., Spanoudakis E., Papatheodorou A., Eleutherakis-Papaiakevou E., Kanellias N., Gavriatopoulou M., Makras P., Kastritis E., Dimopoulos M.A. (Athens, Thessaloniki, Alexandroupolis)

P34

OUTCOME OF COVID-19 INFECTION AMONG MYELOMA PATIENTS ON LENALIDOMIDE MAINTENANCE

Kırcalı E., Cengiz Seval G., Koçak Toprak S., Arslan Ö., Topçuoğlu P., Özcan M., İlhan O., Gürman G., Beksaç M. (Ankara)

P35

RECOVERY OF OCULAR EVENTS WITH LONGER-TERM FOLLOW-UP IN THE DREAMM-2 STUDY OF SINGLE-AGENT BELANTAMAB MAFODOTIN (BELAMAF) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM)

Lonial S., Nooka A.K., Thulasi P., Badros A.Z., Jeng B.H., Callander N.S., Sborov D., Zaugg B.E., Popat R., Degli Esposti S., Byrne J., Opalinska J., Baron J., Piontek T., Gupta I., Dana R., Farooq A.V., Jakubowiak A. (Atlanta, Baltimore, Madison, Salt Lake City, London, Upper Providence, Boston, Chicago)

P36

HORIZON (OP-106): MELFLUFEN PLUS DEXAMETHASONE IN 55 PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA WITH EXTRAMEDULLARY DISEASE—SUBGROUP ANALYSIS

Richardson P., Mateos M., Oriol A., Larocca A., Cavo M., Rodríguez-Otero P., Leleu X., Norkin M., Nadeem O., Hiemenz J., Hassoun H., Touzeau C., Alegre A., Paner A., Maisel C., Mazumder A., Raptis A., Puig N., Zamagni E., Thuresson M., Harmenberg J., Harlin O., Bladé J. (Boston, Salamanca, Badalona, Torino, Bologna, Pamplona, Poitiers, Jacksonville, Gainesville, New York, Nantes, Madrid, Chicago, Dallas, Glendale, Pittsburgh, Stockholm, Barcelona)

P37

HORIZON (OP-106): MELFLUFEN PLUS DEXAMETHASONE (DEX) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)

EXPOSED TO PRIOR ALKYLATOR THERAPY—SUBGROUP ANALYSIS

Rodríguez-Otero P., Mateos M.V., Oriol A., Larocca A., Bladé J., Cavo M., Leleu X., Norkin M., Nadeem O., Hiemenz J., Hassoun H., Touzeau C., Alegre A., Paner A., Maisel C., Mazumder A., Raptis A., Puig N., Thuresson M., Harmenberg J., Harlin O., Richardson P. (Pamplona, Salamanca, Badalona, Torino, Barcelona, Bologna, Poitiers, Jacksonville, Boston, Gainesville, New York, Nantes, Madrid, Chicago, Dallas, Glendale, Pittsburgh, Stockholm)

P38

IMMUNE THROMBOCYTOPENIA ASSOCIATED WITH MULTIPLE MYELOMA

Kırcalı E., Cengiz Seval G., İlhan O., Gürman G., Beksaç M. (Ankara)

P39

DISTINCTIVE FEATURES OF THE TUMOR MICROENVIRONMENT IN DARATUMUMAB-NAÏVE vs -REFRACTORY PATIENTS MAY EXPLAIN THE DIFFERENTIAL RESPONSE TO ANTI-PDL1 AND ANTI-CD-38 COMBINATION TREATMENT IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA

Raval A., Green C., Fritsch E.W., Ma C., Kockx M., Hamidi H., Huang H., Colburn D., Wong S.W., Adamkewicz J.I., Cho H.J. (South San Francisco, Basel, Antwerp, Mississauga, San Francisco, New York)

P40

PATIENT-REPORTED EXPERIENCES DURING AND FOLLOWING TREATMENT WITH BELANTAMAB MAFODOTIN (BELAMAF) FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) IN THE DREAMM-2 STUDY

Eliason L., Correll J., Martin M., Cardellino A., Opalinska J., Piontek T., Gorsh B., Sapra S., Popat R. (Upper Providence, Seattle, London)

P41
ASSESSMENT OF EYE FUNCTION IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): BASELINE OCULAR DATA FROM THE DREAMM-2 TRIAL
Popat R., Kazantzi A., Farooq A.V., Thulasi P., Lonial S., Jakubowiak A., Badros A.Z., Jeng B.H., Opalinska J., Baron J., Piontek T., Byrne J., Womersley L., Gupta I., Degli Esposti S. (London, Chicago, Atlanta, Baltimore, Upper Providence)

P42
ANCHOR (OP-104): MELFLUFEN PLUS DEXAMETHASONE (DEX) AND DARATUMUMAB (DARA) OR BORTEZOMIB (BTZ) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) REFRACTORY TO AN IMID AND/OR A PROTEASOME INHIBITOR (PI) – UPDATED EFFICACY AND SAFETY
Ocio E., Efebera Y., Hájek R., Granel M., Maisnar V., Straub J., Eveillard J.R., Karlin L., Ribrag V., Mateos M.V., Oriol A., Sydvaner M., Norin S., Mannikko S., Pour L. (Santander, Columbus, Ostrava, Barcelona, Hradec Králové, Brest, Pierre-Benite, Villejuif, Salamanca, Spain, Badalona, Stockholm, Brno)

P43
DREAMM-2: SINGLE-AGENT BELANTAMAB MAFODOTIN (BELAMAF) EFFECTS ON PATIENT-REPORTED OUTCOME (PRO) MEASURES IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
Popat R., Lonial S., Voorhees P.M., Degli Esposti S., Gupta I., Opalinska J., Sapra S., Gorsh B., He Z., Kleinman D., Schaumberg D., Loubert A., Meunier J., Regnault A., Eliason L. (London, Atlanta, Charlotte, Upper Providence, Rochester, Salt Lake City, Lyon)

P44
BENDAMUSTINE-BORTEZOMIB-DEXAMETHASONE (BVD) IN HEAVILY PRETREATED MULTIPLE MYELOMA: OLD/NEW IN NOVEL AGENTS' ERA
Cerchione C., Catalano L., Rocco S., Palmieri S., Nappi D., Pareto A.E., Ronconi S., Ceccolini M., Pane F., Martinelli G., Ferrara F. (Meldola, Napoli)

P45
CARTITUDE-1 STUDY OF CILTACABTAGENE AUTOLEUCEL IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: ASSESSMENT OF HEALTH-RELATED QUALITY OF LIFE
Martin T., Lin Y., Agha M., Cohen A., Htut M., Stewart A., Hari P., Berdeja J., Madduri D., Usmani S., Yeh T.M., Allred A., Olyslager Y., Banerjee A., Goldberg J., Schechter J., Jackson C., Deraedt W., Gries K., Fastenau J., Wu X., Carrasco-Alfonso M., Akram M., Hossain F., Jakubowiak A., Jagannath S. (San Francisco, Rochester, Pittsburgh, Philadelphia, Duarte, Toronto, Milwaukee, Nashville, New York, Charlotte, Raritan, Spring House, Beerse, Piscataway, Chicago)

P46
POMALIDOMIDE/DEXAMETHASONE COMBINATIONS ARE AN EFFECTIVE SALVAGE REGIMEN FOR MULTIPLE MYELOMA (MM) PATIENTS RELAPSED AND/OR REFRACTORY TO DARATUMUMAB (DARA)
Brioli A., Mancuso K., Binder M., Ernst T., Hilgendorf I., Zamagni E., Heide F., Stauch T., Hochhaus A., von Lilienfeld-Toal M. (Jena, Bologna, Halle)

P47
EVOLVING OUTCOMES IN MM REAL-WORLD PRACTICE: 20-YEARS SINGLE CENTER EXPERIENCE
Bianco O., Bellofiore C., Romano A., Leotta V., Del Fabro V., Elia F., Di Raimondo F., Conticello C. (Catania)

P48
EARLY OLIGOSECRETORY/FREE LIGHT CHAIN ESCAPE AND THE IMPORTANCE OF REGULAR SFLC ASSESSEMENT. A REAL-LIFE UNICENTRIC RETROSPECTIVE STUDY
Markovic U., Romano A., Del Fabro V., Bellofiore C., Bulla A., Di Raimondo F., Conticello C. (Catania)

P49
A HEALTHCARE PROFESSIONAL SURVEY TO UNDERSTAND PATIENT ASSESSMENT, MANAGEMENT AND ADMINISTRATION PRACTICES IN THE TREATMENT OF MULTIPLE MYELOMA PATIENTS WITH CARFILZOMIB
Wetten S., Di Pietrantonio K., Sumners E., Trewartha F., Fowler G., Brailean A. (Uxbridge, Bollington)

P50

CARFILZOMIB-LENALIDOMIDE-DEXAMETHASONE IN THE MANAGEMENT OF LENALIDOMIDE-REFRACTORY MULTIPLE MYELOMA

Cerchione C., Martinelli G., Nappi D., Pareto A.E., Di Perna M., Ferrara K., Musuraca G., Lucchesi A., Pane F., Catalano L. (*Meldola, Napoli*)

P51

IMMUNOTHERAPY IN MULTIPLE MYELOMA: EXPERIENCE OF THE MULTIPLE MYELOMA GIMEMA LAZIO GROUP

Vozella F., Siniscalchi A., Rizzo M., Za T., Antolino G., Coppetelli U., Piciocchi A., Andriani A., Annibali O., De Rosa L., Cimino G., La Verde G., De Stefano V., Cantonetti M., Caravita di Toritto T., Petrucci M.T. (*Roma*)

P52

LONG-TERM CONTROL OF DISEASE IN MYELOMA PATIENTS TREATED AT THE SECOND RELAPSE WITH MONOCLONAL ANTIBODIES: A REAL-WORLD SINGLE CENTER EXPERIENCE

Markovic U., Romano A., Leotta V., Del Fabro V., Bellofiore C., Bianco O., Curto Pelle A., Di Raimondo F., Conticello C. (*Catania*)

P53

EXTRAMEDULLARY MULTIPLE MYELOMA OF THE ORAL CAVITY: A MONOCENTRIC CASE SERIES

Brescini M., Fazio F., Petrucci M.T. (*Roma*)

P54

OUTCOMES IN MULTIPLE MYELOMA THAT DEBUTS WITH PLASMACYTOMA: AN OBSERVATIONAL STUDY

Pinzón S., Bakali S., Izquierdo I., Garcia J., Almanzar H.P., Hernández C., Gómez A., Martín-Consuegra S., Moreno M., González E., Rubio A., Osuna C., Iborra A., Delgado P. (*Zaragoza*)

P55

USE OF DARATUMUMAB IN RELAPSE/REFRACTORY MULTIPLE MYELOMA PATIENTS IN THE REAL WORLD

Solé-Rodríguez M., Zapata-Bautista R., Domínguez-Rodríguez J.F. (*Huelva*)

P56

BELANTAMAB MAFODOTIN IN HEAVILY TREATED RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS: A CASE-SERIES FROM A REAL-LIFE EXPERIENCE

Fazio F., Brescini M., Lapietra G., Petrucci M.T. (*Roma*)

4. SPECIAL CONDITIONS

P57

NATURAL HISTORY OF SKELETAL RELATED EVENTS IN PATIENTS WITH MULTIPLE MYELOMA AT DIAGNOSIS AND AT FIRST RELAPSE: RESULTS FROM A SINGLE CENTER STUDY IN 620 PATIENTS WHO RECEIVED NOVEL ANTIMYELOMA AGENTS

Terpos E., Kanellias N., Kastritis E., Gavriatopoulou M., Koutoulidis V., Ntanasis-Stathopoulos I., Papanota A.M., Fotiou D., Migkou M., Eleutherakis-Papaiakovou E., Malandrakis P., Bagratuni T., Roussou M., Mouloupoulos L.A., Dimopoulos M.A. (*Athens*)

P58

WHOLE BODY LOW DOSE CT IN NEWLY DIAGNOSED MULTIPLE MYELOMA: DIAGNOSTIC VALUE OF PERIPHERAL MEDULLARY PATTERNS OF ATTENUATION

Terpos E., Koutoulidis V., Ntanasis-Stathopoulos I., Gavriatopoulou M., Zagouri F., Klapa I., Bouladaki A., Malandrakis P., Papanota A.M., Fontara S., Kastritis E., Mouloupoulos L.A., Dimopoulos M. (*Athens*)

P59

CORONAVIRUS DISEASE (COVID-19) IN PATIENTS WITH MULTIPLE MYELOMA:
REPORTED BY THE MULTIPLE MYELOMA GIMEMA LAZIO GROUP

Fazio F., Lapietra G., Anaclerico B., Annibali O., Antolino G., Cupelli L., Brescini M., De Rosa L., Fiorini A., Franceschini L., Gumenyuk S., Poggiali R., Rosati S., Za T., Piciocchi A., Petrucci M.T. (Roma, Viterbo, Latina, Frosinone)

P60

MANAGEMENT OF HEMATOLOGICAL CANCER PATIENTS IN SARS-COV-2 PANDEMIC:
FOCUS ON MULTIPLE MYELOMA PATIENTS IN A SICILIAN HOSPITAL

Del Fabro V., Romano A., Bellofiore C., Bulla A., Garibaldi B., Markovic U., Di Raimondo F., Conticello C. (Catania)

P61

TELEMONITORING IN HAEMATO-ONCOLOGICAL PATIENTS: HIT OR MISS?

Hradská K., Popkova T., Skorupova M., Mihalyova J., Jelinek T., Navratil M., Benkova K., Plonkova H., Zuchnicka J., Gumulec J., Hajek R. (Ostrava)

P62

EMPOWERING PATIENTS IN THE FACE OF A PANDEMIC – A MULTI-DISCIPLINARY REMOTE
MONITORING CLINIC FOR A PATIENT-CENTRED APPROACH IN MYELOMA

Lecat C., Camilleri M., DeSilva D., McCourt O., Worthington S., Smith M., Hart A., Uddin I., Roche C., Fisher A., Yong K. (London)

P63

IMPLICATIONS OF INTERLEUKIN-6 (IL-6)-BLOCKADE FOR SEVERE COVID-19 INFECTION
IN PATIENTS WITH MULTIPLE MYELOMA

Sgherza N., Curci P., Strafella V., Rizzi R., Musto P. (Bari)

P64

AUTOLOGOUS STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA PATIENTS OVER 60 YEARS:
MEL200 VERSUS MEL140

Solé-Rodríguez M., Zapata-Bautista R., Palma-Vallellano A. (Huelva)

P65

PEGFILGRASTIM VERSUS FILGRASTIM IN THE SUPPORTIVE CARE OF HEAVILY PRETREATED MULTIPLE
MYELOMA IN TREATMENT WITH POMALIDOMIDE-DEXAMETHASONE

Cerchione C., Martinelli G., Nappi D., Pareto A.E., Lucchesi A., Musuraca G., Ronconi S., Pane F., Catalano L. (Meldola, Napoli)

P66

POMALIDOMIDE-DEXAMETHASONE IN THE MANAGEMENT OF HEAVILY PRETREATED MULTIPLE
MYELOMA

Cerchione C., Martinelli G., Nappi D., Pareto A.E., Di Perna M., Ferrara K., Ronconi S., Cangini D., Giannini M.B., Di Battista V., Pane F., Catalano L. (Meldola, Napoli)

P67

SAFETY AND EFFICACY OF RECOMBINANT HUMAN HYALURONIDASE-FACILITATED SUBCUTANEOUS
INFUSION OF IMMUNOGLOBULINS IN PATIENTS WITH MULTIPLE MYELOMA

Pavan L., Barilà G., Vedovato S., Leoncin M., Berno T., Branca A., Piazza F., Semenzato G., Zambello R. (Padova)

P68

USE OF DIRECT ORAL ANTICOAGULANTS AS PROPHYLAXIS OR TREATMENT OF VENOUS
THROMBOEMBOLISM IN PATIENTS WITH MULTIPLE MYELOMA ON IMMUNOMODULATORY DRUGS

Aguilar C., Dueñas A.B, Sevil F., Dominguez C. (Soria)

P69

USE OF IBRUTINIB OFF-LABEL IN WALDENSTROM'S MACROGLOBULINEMIA
CHEMOTHERAPY REFRACTORY PATIENTS

Solé-Rodríguez M., Díaz-Roldán B., Zapata-Bautista R. (*Huelva*)

P70

TRIPLE HEMATOLOGICAL DIAGNOSIS: A CLINICAL CHALLENGE

Pinzón S., García J., Bakali S., Hernández C., Gómez A., Martin-Consuegra S.,
Moreno M., González E., Rubio A., Osuna C., Iborra A., Delgado P. (*Zaragoza*)

P71

EUROPEAN HEMATOLOGY ASSOCIATION (EHA) SCIENTIFIC WORKING GROUPS:
THE POWER OF COLLABORATION

Cerisoli F., Gribben J., Sonneveld P., Dreyling M. (*The Hague, Rotterdam, London, Munich*)

P72

PLASMA CELL LEUKEMIA: ABOUT A CATASTROPHIC CASE

Pinzón S., Bakali S., Garcia A., Diez R., Anso V., Hernández C., Gómez A.,
Martin-Consuegra S., Moreno M., González E., Delgado P. (*Zaragoza*)

Enjoy the virtual experience!

SCIENTIFIC BOARD

Mario Boccadoro (Italy)
Hermann Einsele (Germany)
Maria-Victoria Mateos (Spain)
Philippe Moreau (France)
Pieter Sonneveld (The Netherlands)

SCIENTIFIC PROGRAM COORDINATORS

Pieter Sonneveld (The Netherlands)
Sonja Zweegman (The Netherlands)

SCIENTIFIC SECRETARIAT

Francesca Gay (Italy)
Niels van de Donk (The Netherlands)

ORGANIZING SECRETARIAT

Studio E.R. Congressi
Via De' Poeti, 1/7 - 40124 Bologna - Italy
Ph +39 051 4210559
Fax +39 051 4210174
E-mail: emnmeeting@ercongressi.it
www.ercongressi.it

2nd Meeting
European Myeloma Network
Virtual | March 3-6, 2021